# Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores

> **NCT03797612** · PHASE2 · WITHDRAWN · sponsor: **Adynxx, Inc.**

## Conditions studied

- Pain, Postoperative

## Interventions

- **DRUG:** Brivoligide Injection 660 mg/6 mL
- **DRUG:** Placebo 6 mL

## Key facts

- **NCT ID:** NCT03797612
- **Lead sponsor:** Adynxx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01
- **Primary completion:** 2022-01
- **Final completion:** 2022-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study initiation delayed due to COVID 19
- **Last updated:** 2020-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03797612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03797612, "Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03797612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*